Argent BioPharma Limited (RGTLF)
OTCMKTS · Delayed Price · Currency is USD
0.0900
0.00 (0.00%)
At close: Apr 23, 2025

Argent BioPharma Company Description

Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide.

The company’s principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer.

It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and RGAI03MW01, which focuses on chronic wound treatment.

The company has collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care.

The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited.

Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

Argent BioPharma Limited
Country Australia
Founded 2014
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
CEO Roby Zomer

Contact Details

Address:
295 Rokeby Road
Subiaco, 6008
Australia
Phone 61 8 6555 2950
Website argentbiopharma.com

Stock Details

Ticker Symbol RGTLF
Exchange OTCMKTS
Fiscal Year July - June
Reporting Currency AUD
SIC Code 2834

Key Executives

Name Position
Sasha Friedman Deputy Chief Executive Officer
Roby Reuven Zomer Co-Founder, Chief Executive Officer, MD and Executive Director
Igor Bluvstein Chief Financial Officer
Shachar Shimony Group General Counsel
Amir Polak Chief Pharmaceutical Development Officer
Sabina Suljakovic Chief Quality and Commercial Officer
Dr. Nadya Lisovoder Chief Medical Officer
Yair Tal Chief Information Security Officer
Rowan Harland Company Secretary
Ana Arhar Oblak Group Financial Controller